Nektar Therapeutics (NASDAQ:NKTR) was downgraded by investment analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued on Thursday.

NKTR has been the topic of several other research reports. Roth Capital set a $45.00 price target on Nektar Therapeutics and gave the company a “buy” rating in a report on Monday, November 13th. Jefferies Group increased their price target on Nektar Therapeutics from $2.12 to $88.00 and gave the company a “buy” rating in a report on Tuesday, January 16th. Canaccord Genuity Group increased their target price on Nektar Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Mizuho increased their target price on Nektar Therapeutics from $30.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, November 14th. Finally, Cowen began coverage on Nektar Therapeutics in a research note on Tuesday, November 7th. They issued an “outperform” rating on the stock. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Nektar Therapeutics has an average rating of “Buy” and a consensus price target of $46.17.

Shares of Nektar Therapeutics (NASDAQ NKTR) opened at $74.64 on Thursday. Nektar Therapeutics has a twelve month low of $12.50 and a twelve month high of $99.02. The firm has a market capitalization of $11,754.96, a price-to-earnings ratio of -103.67 and a beta of 2.04. The company has a current ratio of 4.14, a quick ratio of 3.99 and a debt-to-equity ratio of 2.91.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.16. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. The company had revenue of $152.90 million for the quarter, compared to analyst estimates of $126.50 million. During the same quarter in the prior year, the firm posted ($0.32) EPS. Nektar Therapeutics’s quarterly revenue was up 321.2% compared to the same quarter last year. equities analysts forecast that Nektar Therapeutics will post -0.76 earnings per share for the current fiscal year.

In other Nektar Therapeutics news, Director Christopher A. Kuebler sold 30,000 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $58.66, for a total value of $1,759,800.00. Following the sale, the director now owns 70,500 shares in the company, valued at $4,135,530. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Howard W. Robin sold 83,333 shares of the stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $75.82, for a total value of $6,318,308.06. Following the completion of the sale, the chief executive officer now owns 333,268 shares in the company, valued at approximately $25,268,379.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 212,576 shares of company stock worth $13,320,003. Insiders own 6.10% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of Nektar Therapeutics by 2.1% during the fourth quarter. BlackRock Inc. now owns 21,431,388 shares of the biopharmaceutical company’s stock valued at $1,279,883,000 after buying an additional 431,269 shares during the period. Vanguard Group Inc. increased its stake in shares of Nektar Therapeutics by 3.0% during the second quarter. Vanguard Group Inc. now owns 14,009,894 shares of the biopharmaceutical company’s stock valued at $273,893,000 after buying an additional 401,914 shares during the period. State Street Corp increased its stake in shares of Nektar Therapeutics by 11.3% during the second quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock valued at $86,179,000 after buying an additional 447,023 shares during the period. Janus Henderson Group PLC increased its stake in shares of Nektar Therapeutics by 87.8% during the third quarter. Janus Henderson Group PLC now owns 3,329,281 shares of the biopharmaceutical company’s stock valued at $79,903,000 after buying an additional 1,556,352 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Nektar Therapeutics by 7.2% during the second quarter. Northern Trust Corp now owns 1,937,352 shares of the biopharmaceutical company’s stock valued at $37,877,000 after buying an additional 130,294 shares during the period. Hedge funds and other institutional investors own 95.76% of the company’s stock.

WARNING: This story was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/nektar-therapeutics-nktr-lowered-to-buy-at-bidaskclub/1857951.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.